The Importance of Being Profiled: Improving Drug Candidate Safety and Efficacy Using Ion Channel Profiling by Gregory J. Kaczorowski et al.
TECHNOLOGY REPORT
published: 13 December 2011
doi: 10.3389/fphar.2011.00078
The importance of being proﬁled: improving drug
candidate safety and efﬁcacy using ion channel proﬁling
Gregory J. Kaczorowski 1, Maria L. Garcia1, Jacob Bode2, Stephen D. Hess2 and UmeshA. Patel 2*
1 Kanalis Consulting, Limited Liability Company, Edison, NJ, USA
2 Millipore Corporation, Billerica, MA, USA
Edited by:
Ralf Franz Kettenhofen, Axiogenesis
AG, Germany
Reviewed by:
Gary Gintant, Abbott, USA
*Correspondence:
Umesh A. Patel , Millipore
Corporation, 15 Research Park Drive,
St. Charles, MO 63304, USA.
e-mail: umesh.patel@
merckgroup.com
Proﬁling of putative lead compounds against a representative panel of relevant enzymes,
receptors, ion channels, and transporters is a pragmatic approach to establish a preliminary
view of potential issues that might later hamper development. An early idea of which off-
target activities must be minimized can save valuable time and money during the preclinical
lead optimization phase if pivotal questions are asked beyond the usual proﬁling at hERG.
The best data for critical evaluation of activity at ion channels is obtained using functional
assays, since binding assays cannot detect all interactions and do not provide information
on whether the interaction is that of an agonist, antagonist, or allosteric modulator. For
ion channels present in human cardiac muscle, depending on the required throughput,
manual-, or automated-patch-clamp methodologies can be easily used to evaluate com-
pounds individually to accurately reveal any potential liabilities. The issue of expanding
screening capacity against a cardiac panel has recently been addressed by develop-
ing a series of robust, high-throughput, cell-based counter-screening assays employing
ﬂuorescence-based readouts. Similar assay development approaches can be used to con-
ﬁgure panels of efﬁcacy assays that can be used to assess selectivity within a family of
related ion channels, such as Nav1.X channels. This overview discusses the beneﬁts of
in vitro assays, speciﬁc decision points where proﬁling can be of immediate beneﬁt, and
highlights the development and validation of patch-clamp and ﬂuorescence-based proﬁling
assays for ion channels (for examples of ﬂuorescence-based assays, see Bhave et al., 2010;
and for high-throughput patch-clamp assays see Mathes, 2006; Schrøder et al., 2008).
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WHY USE IN VITRO PROFILING ASSAYS TO UNDERSTAND
LEAD SELECTIVITY AND SPECIFICITY?
Thedrugdiscovery anddevelopment process is long,and resource-
intensive, often fraught with unforeseeable pitfalls, and historically
challenged by low probability of success (Tollman et al., 2011).
However, vast unmet medical needs justify the efforts expended
in this area of research, and new methodologies are always being
explored to streamline the research process and improve the suc-
cess rate of drug registration. Perhaps the most important factor
at the beginning of any drug discovery project, regardless of the
target, is the identiﬁcation of the best lead structure amongst the
collection of hits discovered either using in silico or through high-
throughput screening techniques to target the process of interest
(Rudolph and Knoﬂach, 2011).
Many factors must be taken into account during lead selection,
such as chemical tractability, chemical stability, physical–chemical
properties, metabolic stability, PK characteristics, protein bind-
ing, and suitability for formulation, in addition to potency and
mechanism of action. However, none are more important than
the speciﬁcity and selectivity of the initial compound. Subjecting
putative leads to thorough scrutiny with respect to potential off-
target pharmacological activities can identify liabilities, some of
them potentially fatal, early on in a program, and thereby allow
medicinal chemists to explore the feasibility of correcting these
problems during exploratory analoging studies. Thus, broad pro-
ﬁling of early hits to determine selectivity, and then use of this
information to prioritize compounds for follow-up, rather than
simply rank-ordering hits based solely on chemical tractability,
can prevent wasting time and effort due to making a poor initial
decision based on a limited and incomplete data set. As an exam-
ple, Millipore offers a wide variety of proﬁling services that utilize
biochemical assays for over 300 kinases and phosphatases and cell-
based functional assays for over 150 G-protein coupled receptors
(GPCRs) and over 50 ion channels that can be utilized to query
compounds at any development stage for speciﬁcity and selectiv-
ity for primary targets, related family members, and for cardiac
safety.
SELECTIVITY AND SPECIFICITY SCREENING
The most straightforward means of generating selectivity data on
a group of hits is to test for activity against a panel of similar targets
from the same and closely related super families of proteins (e.g.,
classes of related enzymes,GPCRs,nuclear receptors, ion channels,
etc.). Such studies provide important data for medicinal chemists
and help focus their structure–activity determinations as part of
a feasibility assessment of a compound’s potential as a lead candi-
date. In addition, these studies also immediately identifymolecules
that are non-selective in their mechanism of action because such
www.frontiersin.org December 2011 | Volume 2 | Article 78 | 1
Kaczorowski et al. Proﬁling assays for ion channels
agents often display pleiotropic activities across an entire family of
related proteins. Functional assays are the preferred methodology
to use for these analyses (see below).
In general, two other means are commonly employed ini-
tially to gather speciﬁcity data (i.e., to identify activities on pro-
teins/processes unrelated to the initial target, some of which could
cause serious adverse drug side effects) on a series of hits (c.f.
Coburger et al., 2010). One is to proﬁle test compounds in vivo
in an animal efﬁcacy model and determine therapeutic index
based on comparing exposure for efﬁcacy versus observed side
effects. The other is to proﬁle hits employing a panel of enzyme
and receptor binding assays, gather the respective proﬁle of off-
target activities predicted for each compound, and assess their
proﬁle in vivo, in an animal model chosen to reveal ancillary phar-
macological activities. Usually, it is assumed that if no untoward
activities are observed in vivo, the risk of any predictable ancillary
pharmacology will be minimal.
LIMITATIONS OF IN VIVO SPECIFICITY AND SELECTIVITY
ASSESSMENT
There are a number of confounding aspects related to using such
in vivo assessment approaches, and the data generated can be
highly misleading without a through understanding gained from
in vitro assays (e.g., Raehal et al., 2011). First, animal experiments
are usually done in rodents, either mice or rats, and while these
species are adequate for tolerability studies to reveal frank toxicity,
they may not be useful for detecting subtle changes in physiology.
In addition, limited exposure and high clearance rates (typical
in rodents) can result in a misleading sense of ancillary phar-
macology. Taken together with the facts that some physiological
response pathways are species-dependent, high protein binding
can mask ancillary pharmacology, and that poly pharmacy of
compounds can cause compensation by altering a number of
inter-related pathways whose individual modulation might other-
wise produce serious consequences, an unremarkable initial in vivo
proﬁle could produce a false sense of security. But most impor-
tantly, the rodent cardiovascular (CV) system is a poor predictor
of CV side effects in humans. This is due to very high heart
rates in the rodent and distinct complements/contributions of
ion channels in the two species (e.g., the cardiac action poten-
tial wave forms are much different when comparing rodent and
human species). Therefore, rodent data, by itself, can yield false-
negative misinformation with respect to adverse CV effects.We do
recognize the utility of rat models for understanding cardiotoxi-
city (Herman et al., 2011); however in general we advise caution
when using this species to assess potential pro-arrhythmic lia-
bilities (i.e., prolongation of QTc intervals, see below). Indeed,
this is one of the reasons that CV liabilities of late stage devel-
opment candidates are traditionally assessed in a dog model,
which is more predictive than rodent of CV safety liabilities in
humans. However, it is not routinely feasible to proﬁle putative
lead structures in the dog due to the need for large quantities of test
compound to initiate both tolerability studies and CV measure-
ments. Employment of cardiomyocytes derived from embryonic
or induced pluripotent stem cells that display the electrophysio-
logical and biochemical properties of normal human heart cells
is currently being explored as a more predictive in vitro model
system for testing a compound’s potential cardiotoxicity, but this
approach is still under development (Braam et al., 2010; Peng
et al., 2010. Therefore, a more informative approach is required
to carry out a formal risk analysis of a lead compound’s poten-
tial liabilities than to simply use cursory rodent in vivo data. It
is critical to have some early means to identify potential prob-
lems that could arise during development of a drug candidate and
to minimize such hazards by selecting the most appropriate lead
class for the focus of medicinal chemists. Moreover, if potential
liabilities exist in an otherwise favorable lead compound, predic-
tive, high-capacity assays must be employed to support Medicinal
Chemistry efforts to dial out these unwanted activities in real
time during the course of structure–activity relationship (SAR)
studies.
It is important to consider the contribution of multiple mecha-
nisms to a physiological response when developing in vivo models
to evaluate speciﬁcity and selectivity and obtaining proof of con-
cept for novel compounds targeting new mechanisms of action.
As the drug industry searches for new druggable targets based
on human genetics, rodent genetic paradigms, and reverse phar-
macology approaches, it is important to check new leads for
poly pharmacy before initiating Medicinal Chemistry campaigns,
just to conﬁrm that pharmacodynamic responses correlate strictly
with the desired molecular action (Weinglass et al., 2008a,b). For
example, the search for agonists of the high-conductance, calcium-
activated potassium channel (maxi-K; KCa1.1) has often revealed
compounds in the past which activate the channel, promote
smooth muscle relaxation, and lower blood pressure in rodents,
i.e., the phenotype expected for a KCa1.1 agonist. However, to
date, all publicly disclosed channel agonists have been observed
to have ancillary pharmacology (e.g., calcium entry blocker activ-
ity, phosphodiesterase inhibitory activity) that promote smooth
muscle relaxation and blood pressure lowering as well, which con-
founds proof-of-concept arguments that a selectiveKCa1.1 agonist
will have therapeutic utility in reversing pathophysiology associ-
ated with smooth muscle hyper-excitability (Garcia et al., 2007).
The importance of proﬁling lead compounds directed against
new mechanisms for ancillary pharmacological activity cannot be
overemphasized.
CROSS-TARGET PROFILING: THE ADVANTAGES OF
FUNCTIONAL ASSAYS
Proﬁling a putative lead compound against a panel represent-
ing a consensus of important enzymes, receptors, ion channels,
and transporters is an excellent way to establish a preliminary
view of potential issues that might hamper development, and
which off-target activities must be minimized accordingly. How-
ever, although enzyme assays are activity-based measurements (N.
B., their interpretation is subject to the conditions chosen for the
assay, especially levels of substrate), the use of binding assays to
assess interaction of test compound with receptors, channels, or
transporters is not as informative as are functional measurements.
The same issues exist, but to a greater extent, with ion channel
proteins. The ability of test compounds to interfere with binding
of speciﬁc ligand probes developed for individual ion channels
is often used as a guide for determining potential drug liabili-
ties. However, it is well known that, unless the sites at which test
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agents interact with a channel are identical or strongly alloster-
ically coupled to that region where the radiolabel probe binds,
potential channel interactions can be missed. Tetrodotoxin (TTX)
is a very potent and selective inhibitor of many voltage-gated
sodium channels. However, except for similar congeners that com-
pete for binding to this inhibitor’s site in the external pore of
the TTX-sensitive sodium channel subtype, the rich pharmacol-
ogy known to exist with this channel family (i.e., the extensive
number of both agonists and antagonists that have previously
beenwell-characterized) is completely undetectable using theTTX
binding reaction (Cestele and Catterall, 2009). Similarly, using
omega conotoxin as a probe for Cav2.2, charybdotoxin as a probe
for Kv1.X or KCa1.1 channels, apamin as a probe for KCa2.X
channels, or sulfonylureas as a probe of K-ATP channels, are addi-
tional insensitivemeans to determine potential off-target activities
directed against these proteins. Indeed, it is known that cono-
toxin binding is highly refractory to modulation by most small
molecule Cav2.2 inhibitors (Abbadie et al., 2010). In the case of
sulfonylureas, binding is to a regulatory subunit associated with
Kir6.2, the pore-forming subunit of the K–ATP channel complex,
and monitoring effects on that binding reaction is conceptually
a poor way to detect direct modulators of the Kir6 channel (see
relevant sections in Hibino et al., 2010). The same criticism could
be applied to many of the probes used to assess interactions with
ligand-gated ion channels or transporters. In the case of trans-
porters, there is no guarantee that using ligands which interact at
a carrier’s substrate binding site is a sensitive means to detect all
compounds that affect transporter function. Thus, there is no bona
ﬁde substitute to deﬁnitively identify putative ion channel or trans-
porter modulators other than by direct measurement of protein
function. This is especially true when evaluating novel chemi-
cal structures without previous pharmacological history, because
many examples of false negatives and false positives have been
noted when using binding protocols to proﬁle such compound
decks.
EXAMPLES OF PROFILING COMPOUNDS ACROSS TARGETS
AND ACROSS CHANNEL FAMILIES
While drug discovery programs typically test the activity of lead
compounds against other related family member targets, and may
also include some critical cardiac targets, a much wider proﬁl-
ing can yield a better understanding of potential liabilities of the
structural class of compounds under consideration. As an exam-
ple, BIRB0796, which was developed as an allosteric inhibitor of
p38 MAP kinase (aka SAPK2A/SAPK2B; Pargellis et al., 2002) was
proﬁled at a single concentration of 10μM in a functional Safety
and Liability Screening Panel consisting of 125 targets (76 GPCRs,
39 Kinases, two Phosphatases, and eight Cardiac Ion Channels).
Table 1 summarizes the activity of BIRB0796 in biochemical assays
employing the kinases and phosphatases. BIRB0796 inhibits the
SAPK2a/SAPK2b enzyme at a novel “DFG-out” allosteric site as
determined fromstudies of the compoundbound tonon-activated
human p38 MAP kinase, and has weak or no inhibition of 15
other kinases (Pargellis et al., 2002). In our studies greater than
50% inhibition of four kinases, including SAPK2B, was observed.
In addition, 10μM BIRB0796 inhibited ﬁve GPCRs (Table 2) and
twoof sevenCardiac IonChannels, hERG,andKv1.5 (Figure 1), by
Table 1 | Activity expressed as percentage inhibition of 10μM
BIRB0796 on 39 kinases and 2 phosphatases within Millipore’s Safety
and Liability Panel.
Kinase/phosphatase Percentage inhibition
Abl(h) 80
AMPK(r) 1
CaMKIIβ(h) 22
CaMKIIγ(h) 11
CaMKII(δ(h) 22
CDK1/cyclinB(h) −6
CDK2/cyclinA(h) −6
CDK2/cyclinE(h) −11
CDK3/cyclinE(h) −10
CDK5/p25(h) 1
CDK5/p35(h) −26
CDK7/cyclinH/MAT1(h) 17
CDK9/cyclin T1(h) −17
Flt1(h) 96
GSK3β(h) −6
IR(h) −3
LKB1(h) 10
Lyn(h) 81
MAPK1(h) −3
MAPK2(h) −10
p70S6K(h) 39
PhKγ2(h) −1
PKA(h) 6
PKBβ(h) −15
PKCμ(h) 13
PKCα(h) 9
PKCβI(h) −17
PKCβII(h) −11
PKCγ(h) 7
PKCδ(h) −15
PKCε(h) 16
PKCζ(h) −3
PKCη(h) −14
PKCθ(h) −29
PKCι(h) 3
PKG1α(h) 15
PKG1β(h) 13
ROCK-II(h) −3
SAPK2a(h) 94
PTP1B(h) 18
TCPTP(h) 17
The 39 kinases are arranged alphabetically from Abl (top) to SAPK2a (near bot-
tom). The two phosphatases are PTP1B and TCPTP. Except for the rat AMPK, all
enzymes and phosphatases were the human form. Red font is used to highlight
the targets where the inhibition observed was >50%.
≥50%. Inhibition of hERG and Kv1.5 channels could raise a ﬂag of
potential cardiac safety concern for this compound. All these data
on BIRB0796, derived from a combination of biochemical and
cell-based functional assays, provide a better insight into the puta-
tive compound’s liabilities than would have been obtained from
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Table 2 | Activity expressed as percentage inhibition of 10μM
BIRB0796 on 76 GPCRs within Millipore’s Safety and Liability Panel.
GPCR Percentage inhibition
5-HT1A 31.0
5-HT2A 99.5
5-HT2B 18.5
5-HT2C 5.5
A1 19.5
A3 20.5
Alpha1A 6.0
Alpha1D 3.5
Alpha2A −4.0
AT1 −2.5
B2 −4.5
BB2 0.0
Beta 1 −6.0
Beta 2 −9.5
BLT1 8.5
C5aR −5.5
CB1 9.0
CB2 80.0
CCK2 2.0
CCR1 −6.0
CCR2B 0.0
CGRP1 0.0
CRF1 13.0
CX3CR1 −12.0
CXCR1 −1.5
CysLT1 2.0
D1 23.0
D2L 53.5
D5 14.0
DP 12.5
EP2 2.5
EP3 7.5
ETA −4.0
ETB 11.0
FP 20.5
FPR1 −4.5
GAL1 −1.5
GnRH/LHRH −20.5
GPR109A −1.0
H1 −1.5
H2 −5.5
H3 91.5
IP1 12.5
LPA1 6.5
LPA3 5.0
M1 46.5
M2 34.5
M3 5.0
MC5 2.0
Motilin receptor 94.5
NK1 12.0
(Continued)
GPCR Percentage inhibition
NK3 17.5
NMU1 22.5
NTR1 −12.0
OPRD1 8.5
OPRK1 −19.0
OPRM1 −2.5
OT 12.5
OX1 12.0
P2Y1 10.5
PAC1 long isoform 3.5
PAF 19.5
PK1 −6.5
PRP 3.0
PTH1 0.0
S1P3 −1.5
SST4 −5.5
TP 32.0
Trypsin-mediated PARs 9.0
TSH −4.0
UT/GPR14 18.5
V1A 2.0
V2 1.0
VPAC1 −2.0
VPAC2 −4.0
Y2 −13.5
Red font is used to highlight the targetswhere the inhibition observedwas>50%.
All GPCRs within Millipore’s Safety and Liability Panel are full length human
isoforms.
the use of binding assays alone. This example illustrates the need
to broadly characterize any potential drug discovery compound
in functional assays to better understand its potential off-target
activities.
For functional assays to be able to provide accurate and
decision-enabling information, it is important to understand how
these assays perform over an extended period of time. This is
best illustrated in the case of Nav channels, where some speciﬁc
channel members, such as Nav1.7 and Nav1.8 are of interest for
development of novel analgesics, but where such compoundsmust
display restricted activity at the brain Nav1.1 and Nav1.2, and car-
diac Nav1.5 isoforms. To identify novel chemical entities with the
desired properties, i.e., state- and use-dependence to effectively
block peripheral Nav1.7 or Nav1.8 channels involved in pain sig-
naling, while sparing block at the cardiac Nav1.5 channel, drug
discovery programs use both biochemical-based assays as well as
manual patch-clamp and automated EPhys assays (Felix et al.,
2004; Kaczorowski et al., 2008). Using IonWorks and PatchXpress
platforms,Millipore can provide rapid turnaround times (within 7
business days from the date of compound receipt) for routine pro-
ﬁling against Nav1.1, Nav1.2, Nav1.3, Nav1.4, Nav1.5, Nav1.6, and
Nav1.7 channels since these assays are sufﬁciently validated and
quality control is followed rigorously. In addition, when develop-
ment of assays using automated platforms is problematic because
the amount of current remaining in cells held at V 1/2 inactivation
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FIGURE 1 | (A) Activity of 10μM BIRB0796 on cardiac ion channels within Millipore’s Safety and Liability Panel. (B) Because of the signiﬁcant inhibition
observed at 10μM, full concentration response curves for hERG and Kv1.5 were carried out with BIRB0796. Calculated IC50 values were 2.3 and 1.1μM for
hERG and Kv1.5, respectively.
is not sufﬁcient to enable robust and reliable IonWorks assays,
additional assays can be provided using manual patch-clamp (e.g.,
Nav1.8).
These assays utilize stable cell lines (e.g., Burbidge et al., 2002;
Clare et al., 2009) and voltage-clamp protocols designed to assess
multiple features of compounds’ interaction with the Nav chan-
nels (Figure 2). A parameter often desired is use-dependent block,
a condition where block accumulates due to high frequency ﬁr-
ing that can be assayed using multiple-pulse protocols. Block of
the inactivated-state of the channel, also known as tonic block,
which is thought to be relevant in the disease state, can also
be determined by selecting a holding potential that inactivates
a certain fraction of the channels, so that one can estimate the
afﬁnity of the test compound for the inactivated state (Ki) and
compare it with resting state block (Kr; see Hondeghem and
Katzung, 1977; Bean et al., 1983). The protocol illustrated in
Figure 2 was designed to efﬁciently proﬁle both modes of inter-
action of test compounds with Nav1.x channels. Quality-control
data for this protocol are shown in Figure 3, where the activity
at pulse 25 for two concentrations of the reference compound,
and the solvent control are shown. Robust-performing stable cell
lines are crucial for these assays; the criteria for initial validation
of these cell lines include current amplitude (we set a typical
threshold of greater than 250 pA), seal resistance on automated
patch-clamp platforms (i.e., is high enough relative to the cur-
rent amplitude obtained with the assay protocol to give acceptable
current resolution; this ranges from hundreds of MΩ to a few
GΩ depending on the seal substrate) percent of cells expressing
the current (the higher, the better) and continued performance
at these levels over at least 25 passages in culture. Data collected
over a 6-month time period show that the assays are robust and
reproducible (Figure 3). Rigorous quality control checks ensure
week-to-week consistencies which are necessary to support Drug
Discovery programs.
Additional speciﬁc custom automated patch-clamp protocols
(see example in Figure 4) can be rapidly developed to iden-
tify inhibitors of Nav1.X channels that preferentially bind to the
inactivated-state of the channel (Hondeghem and Katzung, 1977;
Bean et al., 1983). We have developed custom protocols, with
all validation data required, in as little as 3 weeks. Example data
obtained using this protocol for seven Nav standards on three
Nav1.X channels, Nav1.2, Nav1.5, and Nav1.6, are summarized
in Table 3 and example data for Nav1.5 are shown in Figure 5.
Lidocaine, tetracaine, lamotrigine, carbamazepine, and riluzole
displayed a large leftward shift in their concentration–response
curve at pulse 2, consistent with the use-dependent mechanism
of block by these agents. Flecainide, on the other hand, displayed
a more modest shift in afﬁnity when comparing pulse 1 and 2,
whereas for phenytoin there is essentially no block at pulse 1 and
pronounced block at pulse 2. These data illustrate that reliable
and efﬁcient automated Ephys assays exist which can support
Medicinal Chemistry programs targeting Nav channels. Similar
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FIGURE 2 | Millipore’s voltage-gated sodium channel IonWorks
Quattro™protocol. Cells are held at a voltage corresponding to ∼V 1/2
inactivation, and subjected to 25 depolarization pulses to 0mV for 20ms.
Pulses are applied every 100ms. Data from Pulse 1 and Pulse 25 are
reported to assess both tonic and use-dependent inhibition.
protocols are in development for other voltage-gated channels,
including Kv channels.
IMPORTANCE OF MEASURING ACTIVITY OF DRUG
CANDIDATES ON ION CHANNELS FOR CARDIAC SAFETY
Off-target activities of drug candidates are particularly relevant
to ion channels expressed in the heart. Untoward modulation of
many of these proteins can result in major safety issues, includ-
ing lethality. Ion channels control conduction of electrical activity
over the heart. They are responsible for efﬁciently orchestrat-
ing both cardiac rate and synchronous contraction of cardiac
muscles comprising the atria and ventricle to allow efﬁcient pump-
ing of blood thorough the body’s vascular system. Identiﬁcation
of compounds found to alter normal cardiac electrocardiogram
(ECG) waveforms, thereby signaling propensity for chronotropic,
ionotropic, or arrhythmogenic activities, typically stops develop-
ment. Therefore, early testing of all drug target lead candidates
against a panel of critical cardiac ion channel targets (e.g., Kv11.1,
Kv7.1,Kir2.1,Nav1.5, andCav1.2) can add substantial value in pri-
oritizing initial screening hits, assessing lead speciﬁcity, supporting
real-timeMedicinal Chemistry SAR studies on selected leads in the
process of identifying development candidates, rescuing programs
FIGURE 3 | Quality-control data for Nav1.1, Nav1.2, Nav1.3, Nav1.4,
Nav1.5, Nav1.6, and Nav1.7 assays collected over a 6month period of
time using IonWorks Quattro. Vehicle control was external buffer with
0.3% DMSO ﬁnal concentration and reference inhibitors consisted of
tetracaine (Nav1.1), lidocaine (Nav1.2, Nav1.3, Nav1.4, Nav1.5, Nav1.6), and
lamotrigine (Nav1.7). Data shown were calculated from Pulse 1 and Pulse
25 (as in Figure 2) and displayed as percentage activation relative to the
ratio of Post-Compound/Pre-Compound pulses. Where 0.3% DMSO had
no effect between the Pre-Compound and the Post-Compound pulses,
this was deﬁned as 100% activation. (Top left panel) vehicle control data.
(Top right) data obtained at P1 with the IC50 concentration of inhibitor.
(Bottom left) data obtained at P25 with the IC50 concentration of inhibitor.
(Bottom right) data from P25 using an IC100 concentration of inhibitor. All
data points are from cells with a minimum of 250 pA of current, and the
mean is shown as the large ﬁlled symbol in each panel. The IC50 dose is
chosen to estimate the block achieved at P25; since the compounds are
state- and use-dependent blockers less than 50% block is frequently
achieved at P1.
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FIGURE 4 | IonWorks Quattro Nav pulse protocol designed specifically
to characterize interaction with the inactivated-state of the channel.
Pulse 1 drives Nav channels primarily into the inactivated state, the 5ms
step back to −120mV relieves the fast inactivation, and the second
depolarizing pulse (Pulse 2) deﬁnes a compound’s ability to bind to the
inactivated-state of the channel.
Table 3 | Potency values for reference Nav inhibitors as determined
with the 2-pulse protocol.
Reference compound Predicted IC50 potency values (μM)
Nav1.2 Nav1.5 Nav1.6
P1 P2 P1 P2 P1 P2
Lidocaine – 8.2 – 4 270 4.7
Tetracaine 18 0.12 19 0.17 9.4 0.08
Lamotrigine – 8.6 – 8.8 – 5.2
Carbamazepine – 12 – 5.7 – 4.6
Flecainide 11 3.2 9.1 3 9.7 2.7
Phenytoin – 5.8 – 6.5 – 7
Riluzole 38 4.7 39 0.77 32 1.4
See Figure 4 for the protocol.
with potential major cardiac safety liabilities that are usually only
revealed at the end of preclinical development, and supporting
ﬁnal stage drug registration efforts. Medicinal chemists ﬁnd real
value in having access to such selectivity data from a cardiac ion
channel panel during lead optimization efforts.
The human ventricular cardiac action potential waveform
(Figure 6, top) is shaped primarily by the activity of six different
ion channels; Nav1.5, Cav1.2, Kv4.2/4.3, Kv7.1 (KCNQ1/KCNE1
channel complex), Kv11.1 (hERG; the Kv11.1 protein is thought to
underlie the IKr current), and Kir2.1 (Roden et al., 2002). Addi-
tional channels (Kv1.5, Kir3.1/3.4) also contribute to the action
potential waveform in atria. The summation of action poten-
tial waveforms over the entire structure of the heart gives rise
to the measurements made in a surface ECG (Figure 6, bottom).
Human genetics demonstrate that mutations in most of the ven-
tricular ion channels listed above can have profound effects on
ECG parameters, such as QTc, QRS, and PR intervals, which
thereby signal potential cardiac safety issues (Nattel and Carls-
son, 2006; Lu et al., 2008). Some of these waveform alterations
may have fatal consequences (e.g., QTc prolongation can lead
to torsades de pointes, which can lead to ventricular ﬁbrillation,
FIGURE 5 | Inhibition of Nav1.5 channels by Nav1.X channel standards
using the inactivated-state IonWorks Quattro protocol (Figure 4). Pulse
1 (P1) and Pulse 2 (P2) data were calculated from the maximum inward Nav
current amplitudes from each depolarizing pulse and are presented as
percentage activation relative to the ratio of Post-Compound/
Pre-Compound pulses. Gray symbols and lines are data from P1, and tan
symbols and lines are from P2.
which can result in sudden cardiac death). Importantly, reduction
of the cardiac rapid delayed rectiﬁer potassium channel caused
by loss-of-function mutations of the hERG channel will prolong
the ventricular action potential, elongate the QTc interval, and
cause a lethal arrhythmia. Gain-of-function mutations in hERG
produce the opposite functional effects on action potentials and
QTc intervals, but could result in either atrial ﬁbrillation (Hong
et al., 2005) or ventricular ﬁbrillation; each condition is potentially
lethal. Loss-of-function mutations in the cardiac sodium chan-
nel, Nav1.5 (Brugada Syndrome), increases QRS interval, slows
conduction and may result in initiation of lethal arrhythmias,
while gain-of-function mutations prolong QTc, thereby increas-
ing probability of the same fatal end point. Inhibition of the
cardiac slow delayed rectiﬁer potassium channel due to loss-of-
function of either the pore-forming subunit, KCNQ1, or of the
beta regulatory subunit, KCNE1, prolongs QTc, while activation
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FIGURE 6 | Human ventricular action potential and surface
electrocardiogram (ECG).The ventricular action potential (indicated in red)
is determined by the activity of several ion channels. When the membrane
potential reaches a threshold value, voltage-gated sodium channels (INa)
rapidly activate and sodium ions enter the cell down their concentration
gradient to cause cell depolarization. INa (Nav1.5), therefore, contributes to
the upstroke of the action potential. Following depolarization, calcium
channels (ICa; Cav1.2) open to allow calcium ions to enter the cell and
initiate the excitation–contraction coupling mechanism. In order to bring the
cell back to its resting state, different potassium channels, such as Ito
(Kv4.2/Kv4.3), IKr (Kv11.1; HERG), IKs (Kv7.1/mink), and IK1 (Kir2.1) become
engaged at different phases of the action potential. The action potential
duration represents the time interval between the action potential upstroke
and return to the resting level. The surface ECG (purple) is the sum of action
potentials over all compartments of the heart. The P wave corresponds to
atrial depolarization, whereas the QRS complex is caused by depolarization
of the ventricle. TheT wave corresponds to repolarization of the ventricle.
of this channel through gain-of-function mutations in KCNQ1
shortens QTc. Both phenotypes increase the probability of sud-
den cardiac death. The same spectrum, with respect to effects on
QTc interval and arrhythmogenic potential, is also produced by
loss- or gain-of-functionmutations in the cardiac inwardly rectify-
ing potassiumchannel,Kir2.1. Finally, gain-of-functionmutations
(Timothy Syndrome) in the L-type calcium channel, Cav1.2, leads
to QTc prolongation, ventricular, and atrial arrhythmias, and can
be fatal, while loss of Cav1.2 function shortens QTc intervals and
increases the possibility of sudden cardiac death, as well. Taken
together, data from studies of human genetics demonstrate that
the consequences of altering function of the major ion conduction
pathways in the heart often result in an increase in mortality. Thus,
drugs which affect these targets can similarly elicit fatal events
(Roden, 2004; Knollmann and Roden, 2008) and it is critical to
identify such liabilities as early as possible in development and take
corrective actions. Indeed as little as 20%block of hERG current by
some drugs that do not affect other cardiac currents can produce
dangerous prolongation of the ventricular action potential (for a
comprehensive analysis of drugs that prolongQT interval, see Red-
fern et al., 2003). As an example for another cardiac ion channel,
we recently proﬁled a compound from a non-cardiac ion chan-
nel program and detected antagonist activity at KCNQ1/minK
channels, which could cause delayed ventricular repolarization
in vivo. At this stage, proﬁling of different chemical series and
multiple representatives of these chemical series can be performed
to provide structure activity relationship data that provided a path
forward in the project. CardiacProﬁler™functional patch-clamp
assays offered by Millipore provide a convenient path to under-
stand potential cardiac liability of potential lead compounds at
the most important eight cardiac ion channels and can serve as an
important component of integrated cardiac risk management.
DETERMINING ACTIVITY ON hERG, Nav1.5, AND Cav1.2
CHANNELS: LIMITATIONS OF LIGAND-BINDING ASSAYS
Several methodologies have been adopted to routinely probe for
interactions of test compounds with three of the major cardiac
ion channel liability targets; hERG, Nav1.5, and Cav1.2. Histor-
ically, the most commonly used technique involves monitoring
the effects of test compounds on binding of selective ligands for
each of these channels to identify potential safety risks. Of these
targets, hERG is the most important to be evaluated, given that:
(1) hERG modulation can produce mortality; (2) as little as 20%
hERG block can have an effect on QTc interval; (3) some drugs
have been withdrawn from the market or received a cautionary
warning because of safety issues (lethal arrhythmias) found to be
associated with their activity against hERG (Table 4); (4) regula-
tory agencies will not approve registration of new drugs without
a data package demonstrating a minimal hERG liability; (5) the
Kv11.1 channel is the most promiscuous ion channel ever charac-
terized in terms of its molecular pharmacology – it is blocked by a
wide variety of molecules,perhaps because the channel’s inner cav-
ity located below the selectivity ﬁlter can accommodate such awide
range of structures – so there is high probability that some inter-
action with novel test compounds might be observed (Fermini
and Fossa, 2003). Although hERG binding assays have been used
in the ﬁeld for many years, this approach is conceptually ﬂawed
when compared with proﬁling actives directly on hERG func-
tion. Many instances of hERG binding by drug candidates have
yielded both false positive and false-negative data during testing
of novel structural series. False positives can be sorted out by sub-
sequent evaluation in a functional assay. However, false negatives
can have disastrous program consequences if the hERG liability
is not detected until a potential preclinical candidate is proﬁled
in vivo in a CV dog. The time wasted and lack of SAR information
on the newly discovered hERG activity usually results in termi-
nation of development efforts. The risk of using hERG binding
assays as the only support for Medicinal Chemistry is simply not
warranted when alternatives exist for employing medium- and
high-capacity functional hERG assay formats.
Similarly, it may be misleading to monitor the effect of test
compounds on batrachotoxin (BTX) binding to Nav1.2 channels
in brain tissue as a surrogate for identifying potential interactions
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Table 4 | Drugs withdrawn due to QT-prolongation.
Drug Date withdrawn Reference
Terodiline 1991 Shah (2006)
Terfenadine (seldane) 1998 Shah (2006)
Mibefradil (posicor) 1998 Shah (2006)
Sertindole 1998 Shah (2006)
Astemizole (hismanal) 1999 Shah (2006)
Grepaﬂoxacin (raxar) 1999 Shah (2006)
Cisapride (propulsid) 2000 http://www.medscape.com/viewarticle/446682
Droperidol 2001 Shah (2006)
Sparﬂoxacin (zagam) 2001 Fluoroquinolones andQT-prolongation research continues http://www.infectiousdiseasenews.com/
article/33493.aspx
Levacetylmethadol 2001 Shah (2006)
Dofetilide 2004 Shah (2006)
Thioridazine 2005 Shah (2006)
Quinidine 2006 Olsson (2010)
Halofantrine ? Lin et al. (2011)
Anzemet (injection form) 2011 Sanoﬁ Aventis (2011)
Pimozide (orap) ? Lin et al. (2011)
Haloperidol (haldol) ? Lin et al. (2011)
Erythromycin ? Lin et al. (2011)
Lidoﬂazine ? Oshiro et al. (2010)
with the cardiac sodium channel. Because (1) the BTX site is
not coupled to all other drug binding sites on sodium channels
(Cestele and Catterall, 2009), (2) the channels under investigation
are distinct (Nav1.5 versus Nav1.2), (3) sodium channel subtype-
selective inhibitors exist (Williams et al., 2007; Schmalhofer et al.,
2008), and (4) electrical environment/biophysical properties can
speciﬁcally inﬂuence Nav1.5 block, testing compounds directly on
Nav1.5 function is a much more meaningful approach.
Lastly, monitoring binding of representative ligands for the
L-type calcium channel from the dihydropyridine, phenylalky-
lamine, and benzothiazepine classes to probe for potential Cav1.2
interactions is likewise ﬂawed. Out of the three ligand classes,
the diltiazem binding assay is probably the most sensitive means
to detect possible channel modulators; however, this assay still
yields false positives and negatives. Such ﬁndings support use of a
functional assay to replace ligand-binding for evaluating potential
Cav1.2 interactions.
DEVELOPMENT OF HIGH-THROUGHPUT FUNCTIONAL
ASSAYS FOR ION CHANNEL MODULATION
Depending on the required throughput, manual, or automated
patch-clampmethods can be used to evaluate compounds individ-
ually against each of the six to eight critical ion channels present
in human cardiac muscle to accurately reveal any potential lia-
bilities. However, using such techniques to assess large numbers
of compounds can be tedious, time-consuming, and costly. The
issue of expanding screening capacity against a cardiac panel
has recently been addressed by developing a series of robust,
high-throughput, cell-based counter-screening assays employing
ﬂuorescence-based readouts. For example, assay conditions were
developed and optimized to establish a high-capacity 384- and
1536-well functional thallium ﬂux assay for the hERG channel
that recapitulates the molecular pharmacology of a wide range
of standard, well-characterized, channel blockers based on their
activitiesmeasured in electrophysiological protocols (Schmalhofer
et al., 2010). These studies were further extended to the analysis
of approximately 1000 compounds randomly chosen to repre-
sent diverse structural classes from ongoing Medicinal Chemistry
programs, where the activities in thallium ﬂux or in a hERG
ligand-binding assaywere comparedwith data obtained from elec-
trophysiology determinations made on the same compound deck.
Subsequent correlations reveal that the thallium ﬂux inhibitory
values correlate more closely with electrophysiology data than do
the ligand-binding results for this series of compounds (Figure 7).
Thus, use of a well-controlled thallium ﬂux assay is an excellent
high-capacity predictive assay of in vitro hERG blocking activity.
Such an assay has supported Medicinal Chemistry efforts to sig-
niﬁcantly dial out problematic off-target interactions with Kv11.1,
while potency was simultaneously enhanced on the primary target
(Garcia and Kaczorowski, unpublished observations).
Robust HTS assays have been developed for Kir2.1,Nav1.5, and
Cav1.2 channels, as well. For example, aHEKhKir2.1 thalliumﬂux
assay operant in 384- or 1536-well format has been established,
validated, and routinely used as a counter-screen in efforts to
develop the molecular pharmacology of other inwardly rectifying
potassium channel targets (Garcia and Kaczorowski, unpublished
observations). It is expected that a similar HTS assay could be con-
ﬁgured with the KCNQ1/KCNE1 channel complex as a probe for
modulators of the cardiac slowdelayed rectiﬁer potassiumcurrent.
Using either FRET dye pairs or single ﬂuorescence dyes to monitor
membrane potential, a routine, robust, and sensitive hNav1.5 HTS
assay has been conﬁgured that is operant in formats that can sup-
port high-density screening with 1536-well plates (Felix et al.,
2004). Use of an agonist initiation protocol allows conﬁguration of
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FIGURE 7 | Correlation between QPatch and high-throughput hERG
assays. For a subset of compounds for which two high-throughput hERG
assays, thallium ﬂux (blue symbol), and 35S-MK499 binding (red symbol)
showed >7-fold difference in potency, the estimated fraction of block in
QPatch hERG recordings correlates to a greater degree with the thallium
ﬂux data Schmalhofer et al. (2010).
assay conditions which yield pharmacologically faithful data when
compared to K inactivation values of literature standards. Finally,
a calcium inﬂux assay was developed to detect state-dependent
Cav1.2 blockers by stably expressing the Cav1.2 channel subunits
(α1C, α2δ1, β2a) along with an inward rectiﬁer potassium chan-
nel, Kir2.3, in HEK cells (Dai et al., 2008; Abbadie et al., 2010).
Cell membrane potential is controlled by bath external potassium
concentrations due to the presence of Kir2.3 and the equilib-
rium between different Cav1.2 states is shifted by controlling cell
membrane potential. By incubating cells with test compounds
at different potassium concentrations, triggering channel open-
ing by depolarizing cells with high potassium, and measuring
increases in internal calcium with a calcium-sensitive dye, state-
dependent Cav1.2 blockers can be detected in an accurate, facile,
and reproducible fashion. Importantly, pharmacological sensitiv-
ity data from all these protocols display good correlation with
patch-clamp results.
This functionalHTS approach to assay cardiac ion channels can
reduce the risk of unwanted side effects and eliminate such liability
early in lead development. The implementation of high-capacity,
robust, facile, accurate, and cost effective, cellular-ﬂuorescence-
based ion channel counter-screening methodologies can support
data delivery on a weekly basis to support Medicinal Chemistry
SAR efforts. Moreover, this strategy can be extended to develop-
ing a CNS liability panel including functional assays for Kv1.X,
Kv2.X, Kv3.X, Kv4.X, Cav2.X, Cav3.X, and KCNQ2-3 using the
same general cell-based approach.
CONCLUSION
Attention to identifying serious off-target activities and support-
ing Medicinal Chemistry efforts to minimize these activities are as
important as the other efforts that go into identifying a potential
drug development candidate. Eliminating ancillary pharmacology
helps to improve therapeutic index which will be beneﬁcial during
clinical trials supporting new drug registration. Often, drug fail-
ures in the clinic result from non-mechanism-based side effects
which could have been identiﬁed and eliminated by proper pro-
ﬁling of lead candidates. Utilizing comprehensive, sensitive, and
well-validated proﬁling assays provides drug developers the ability
to ask the crucial questions early and often during the preclinical
development process, which should save time, money, and avoid
nasty surprises.
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